All Photos(1)
Key Documents
Safety Information
SHC204
MISSION® TRC2 pLKO.5-puro TurboGFP™ shRNA Control Plasmid DNA
shRNA sequence targeting tGFP
Synonym(s):
MISSION® Control Vectors
Sign Into View Organizational & Contract Pricing
Select a Size
1 AMP
¥483.72
All Photos(1)
Select a Size
Change View
1 AMP
¥483.72
About This Item
Recommended Products
Quality Level
product line
MISSION®
concentration
500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)
shipped in
dry ice
storage temp.
−20°C
Looking for similar products? Visit Product Comparison Guide
Related Categories
1 of 4
This Item | P9599 | P8340 | P8215 |
|---|---|---|---|
| form DMSO solution | form DMSO solution | form DMSO solution | form DMSO solution |
| Quality Level 300 | Quality Level 300 | Quality Level 300 | Quality Level 300 |
| storage temp. 2-8°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
| shipped in wet ice | shipped in - | shipped in - | shipped in - |
General description
The MISSION® TRC2 Control Vector pLKO-puro TurboGFP™ shRNA is a 7518 base pair lentivirus plasmid vector that contains an shRNA sequence targeting TurboGFP™. This vector is in the TRC2 pLKO-puro plasmid backbone, which contains the WPRE. The TurboGFP™ shRNA Control Vector is useful as a positive knockdown control in experiments using the MISSION® TurboGFP™ positive control vector in cell lines expressing TurboGFP™.[1][2] TurboGFP™ is an improved variant of the green fluorescent protein copGFP cloned from copepoda Pontellina plumata.
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids (SHP001). The TRC2 TurboGFP™ shRNA Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids (SHP001). The TRC2 TurboGFP™ shRNA Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
Application
Small interfering RNAs (siRNAs) expressed from short hairpin RNAs (shRNAs) are a powerful way to mediate gene specific RNA interference (RNAi) in mammalian cells. The MISSION product line is based on a viral vector-based RNAi library against annotated mouse and human genes. shRNAs that generate siRNAs intracellularly are expressed from amphotropic lentivirus viral particles, allowing screening in a wide range of mammalian cell lines. In these cell lines, MISSION shRNA clones permit rapid, cost efficient loss-of-function and genetic interaction screens.
To see more application data, protocols, vector maps visit sigma.com/shrna.
Legal Information
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
TurboGFP is a trademark of Evrogen Co.
recommended
Product No.
Description
Pricing
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Restrictive influence of SAMHD1 on Hepatitis B Virus life cycle.
Sommer AF
Scientific Reports, 6, 26616-26616 (2016)
Miguel A Gonzalez-Lozano et al.
Scientific reports, 6, 35456-35456 (2016-10-18)
Development of the brain involves the formation and maturation of numerous synapses. This process requires prominent changes of the synaptic proteome and potentially involves thousands of different proteins at every synapse. To date the proteome analysis of synapse development has
Michael Gruet et al.
Biology, 9(2) (2020-02-27)
Metastasis is associated with poor prognosis in breast cancer. Although some studies suggest beta-blockers increase survival by delaying metastasis, others have been discordant. This study provides both insights into the anomalous findings and identifies potential biomarkers that may be treatment
Luisa Mori et al.
Journal of virology (2020-11-27)
HIV transcription requires assembly of cellular transcription factors at the HIV-1promoter. The TFIIH general transcription factor facilitates transcription initiation by opening the DNA strands around the transcription start site and phosphorylating the C-terminal domain for RNA polymerase II (RNAPII) for
R Zufferey et al.
Journal of virology, 73(4), 2886-2892 (1999-03-12)
The expression of genes delivered by retroviral vectors is often inefficient, a potential obstacle for their widespread use in human gene therapy. Here, we explored the possibility that the posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) might help resolve
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
